Study of Secukinumab With 2 mL Pre-filled Syringes

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: Secukinumab 2 mL form
Drug: Secukinumab 1 mL form
Drug: Placebo

Registration Number: NCT02748863

Lead Sponsor: Novartis Pharmaceuticals

Brief Summary: The aim of the study was to demonstrate efficacy, safety and tolerability of 2 mL pre-filled syringe of 300 mg secukinumab in treatment of moderate to severe plaque psoriasis.

Detailed Description: This is a 52-weeks multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in 24 subjects with moderate to severe plaque-type psoriasis.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 214

Inclusion Criteria

Subjects eligible for inclusion in this study must fulfill all of the following criteria:

Subjects must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated informed consent before any study related activity is performed. Where relevant, a legal representative will also sign the informed study consent according to local laws and regulations.
Men or women of at least 18 years of age at the time of Screening.
Chronic plaque-type psoriasis present for at least 6 months and diagnosed before Randomization.
Moderate to severe psoriasis as defined at Randomization by:
- PASI score of 12 or greater, and
- IGA mod 2011 score of 3 or greater (based on a scale of 0 - 4), and
- Body Surface Area (BSA) affected by plaque-type psoriasis of 10% or greater.
Candidate for systemic therapy. This is defined as a subject having moderate to severe chronic plaque-type psoriasis that is inadequately controlled by
- Topical treatment and/or
- Phototherapy and/or
- Previous systemic therapy

Exclusion Criteria

Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and guttate psoriasis) at Screening or Randomization.
Ongoing use of prohibited treatments. Washout periods detailed in the protocol have to be adhered to. Subjects not willing to limit UV light exposure (e.g., sunbathing and/or the use of tanning devices) during the course of the study will be considered not eligible for this study since UV light exposure is prohibited.

Note: administration of live vaccines 6 weeks prior to Randomization or during the study period is also prohibited.
Previous exposure to secukinumab (AIN457) or any other biologic drug directly targeting IL-17 or the IL-17 receptor.
Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days until the expected pharmacodynamic effect has returned to baseline, whichever is longer; or longer if required by local regulations.
Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system treated or untreated within the past 5 years, regardless of whether there is evidence of local recurrence or metastases (except for Bowen's disease, or basal cell carcinoma or actinic keratoses that have been treated with no evidence of recurrence in the past 12 weeks; carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed).
History of hypersensitivity to any of study drug constituent

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Secukinumab 2 mL form	Secukinumab 2 mL form	Secukinumab 300 mg, provided in a 2 mL pre-filled syringe
Secukinumab 1 mL form	Secukinumab 1 mL form	Secukinumab 300 mg provided in 2 pre-filled syringes of 1 mL/150 mg (current approved form)
Placebo	Placebo	Placebo, provided in a 2 mL pre-filled syringe Placebo, provided in a 1 mL pre-filled syringe

Primary Outcome Measures

Name	Time	Method
Participants With IGA Mod 2011 0 or 1 After 12 Weeks of Treatment	12 weeks	The Investigator's Global Assessment (IGA) mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. Treatment success was defined as achievement of IGA mod 2001 score of 0 or 1. Number of participants who achieved IGA mod 2011 0 or 1 and improved by at least 2 points on the IGA scale compared to baseline
Participants With Psoriasis Area and Severity Index (PASI) 75 Response After 12 Weeks of Treatment	12 weeks	Number of participants who achieved ≥ 75% reduction in PASI compared to baseline PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

Secondary Outcome Measures

Name	Time	Method
Participants With PASI 90 After 12 Weeks of Treatment	12 weeks	Number of participants who achieved ≥ 90% and 100% reduction in PASI compared to baseline
Number of Participants With PASI 100 Response After 12 Weeks of Treatment	12 weeks	Participants who achieved 100% reduction in PASI compared to baseline
Number of Participants Achieving PASI 50/75/90/100 Response or IGA 0 or 1 Response	up to week 52	PASI response over time up to week 52: Number of participants who achieved ≥ 50%, 75%, 90% and 100% reduction in PASI and achieve IGA mod 2011 0 or 1 and improved by at least 2 points on the IGA scale compared to baseline